There are numerous intra-and postoperative factors which have been shown to affect overall outcome. However, not all of them can reliably be predicted or modified in a way to positively affect overall outcome. Recognition of such factors and aggressive attempts at appropriate intervention may reduce overall risk more than preoperative management in isolation. Without defining and subsequently targeting intra-and postoperative risk factors, the benefit of preoperative cardiac management will be limited.
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Preoperative cardiovascular management is an essential component of overall perioperative cardiovascular care. It involves preoperative detection and management of cardiovascular disease, and prediction of both short-and longterm cardiovascular risk. It thereby not only affects anaesthetic perioperative management (e.g. choice of anaesthetic drug and method, type of monitoring, postoperative care) but also surgical decision-making (e.g. postponement, modification, and cancellation of surgical procedure). By modifying intra-and postoperative patient care, preoperative cardiac management is hoped to improve overall perioperative outcome. The immediate aims of preoperative cardiac management are: (i) identification of patients with potentially life-threatening cardiac disease that requires preoperative assessment and treatment by a cardiologist; (ii) identification of the most appropriate testing and avoidance of unnecessary testing (an important aspect because non-invasive and invasive testing are not only associated with patient discomfort and financial burden, but also with morbidity and mortality related to the test procedure, false test results, and postponement of required surgery); and (iii) identification and implementation of most appropriate medical (e.g. initiation, continuation, or optimization of cardiovascular medication) and interventional cardiovascular treatment strategies (e.g. preoperative coronary revascularization or cardiac valve replacement). The ultimate goal of preoperative cardiovascular management is to improve overall patient outcome. This requires individualized management.
Preoperative assessment
Active cardiac conditions, a high-risk surgical procedure, and poor exercise tolerance are the strongest independent predictors of adverse perioperative cardiac outcome.
Active cardiac conditions
Active/unstable cardiac conditions [unstable angina pectoris, acute heart failure, significant cardiac arrhythmias, symptomatic valvular heart disease (VHD), and recent myocardial infarction with residual myocardial ischaemia] are associated with very poor perioperative outcome. They thus need to be identified and, if present, evaluated and treated by a cardiologist according to respective national or international guidelines. Subsequent management (delay, modification, or cancellation of planned procedure) will depend on test results and response to treatment.
Heart failure
Heart failure is a major independent predictor of adverse perioperative outcome in non-cardiac surgery. 2 3 It carries a greater perioperative risk than ischaemic heart disease. 2 The perioperative prognostic value of heart failure with preserved left ventricular (LV) ejection fraction (previously referred to as diastolic heart failure) remains to be determined. The present guidelines on perioperative cardiac care by the European Society of Cardiology (ESC) 1 recommend comparable perioperative management in patients with impaired and preserved LV ejection fraction. Patients with suspected or known heart failure should undergo preoperative evaluation by a specialist to assess the severity of the disease and to ensure optimal medical therapy. The findings on stress echocardiography and the serum concentrations of brain natriuretic peptide (BNP) or its inactive precursor N-terminal pro-B-type natriuretic peptide (NT-proBNP) may be used for risk stratification. This patient population must be expected to be taking multiple, long-term medications, including angiotensin-converting enzyme (ACE) inhibitors, angiotensin-II-receptor blockers, b-blockers, aldosterone antagonists, and diuretics, all with associated side-effects (mostly electrolyte disturbances, renal insufficiency, and intraoperative therapy-resistant hypotension). As there is evidence that the perioperative use of ACE inhibitors, b-blockers, statins, and aspirin improves outcome in patients with LV dysfunction undergoing major vascular surgery, perioperative continuation of such therapy is recommended in this patient population.
Valvular heart disease
As patients with VHD are, in general, at increased risk of perioperative cardiac complications during non-cardiac surgery, echocardiography should be considered in all patients with suspected VHD (class of recommendation IIa, level of evidence grade B) (for definitions of class of recommendation and level of evidence, see Tables 1 and 2 ). In all patients with severe VHD, clinical and echocardiographic evaluation should be performed (I, C) and, if indicated, appropriately treated before operation.
Of all forms of VHD, severe aortic stenosis (AS) (aortic valve area,1 cm 2 or ,0.6 cm 2 m 22 ) carries the highest perioperative cardiovascular morbidity and mortality in non-cardiac surgery. The key factors in the preoperative decision-making are severity of stenosis and clinical condition. The preoperative management of patients with asymptomatic but severe AS remains problematic. They usually tolerate low-to intermediate-risk surgery. If undergoing high-risk surgery, evaluation by a specialist is advisable. In medical patients with asymptomatic severe AS, independent predictors of adverse outcome were female sex, peak aortic-jet velocity, and BNP at baseline. 4 The score which was developed on these independent predictors may be useful in selecting those patients who might benefit from preoperative valve replacement or balloon aortic valvuloplasty. Management of symptomatic patients with severe AS is particularly challenging. These and certain asymptomatic patients with severe AS undergoing high-risk surgery are candidates for aortic valve replacement which should preferably be performed before non-cardiac surgery. In patients with severe AS who cannot undergo surgical valve replacement (advanced age, presence of severe LV dysfunction, multiple and serious co-morbidities, relative urgency of surgery), preoperative transcatheter valve implantation (transapical or transfemoral) should be considered. 5 Considering the very poor short-term prognosis in general, and the very poor 
Functional capacity
Preoperative functional status is probably the most important predictor of perioperative outcome. Low exercise tolerance is associated with poor perioperative outcome.
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The main purpose of preoperative assessment of functional capacity is to predict the individual's ability to increase oxygen delivery in the perioperative period. There are several methods of assessing exercise tolerance.
Duke Activity Status Index
The Duke Activity Status Index (DASI) is a structured questionnaire that grades exercise ability on the basis of a series of questions related to exercise equivalences ranging from the ability to wash and dress without breathlessness to strenuous activity such as swimming and singles tennis. 16 
Incremental shuttle walk test
The incremental shuttle walk test (ISWT) is widely used for the assessment of cardiopulmonary reserve. It has the patient walk up and down a usually 10 m course (shuttle) at a speed dictated by an audio signal, with the walking speed being slowly increased at timed intervals. The test is terminated either by the patient who feels too fatigued to continue walking at the speed set by the audio signal or by the operator when the patient fails to complete the 10 m course within the allotted time. The distance completed by the patient when the test is terminated is a measure of functional capacity and correlates with peak oxygen consumption in various conditions. 20 21 Cut-off values for walking distance predicting adverse postoperative outcome will depend on the type of surgery and have been reported as ,350-400 m in patients undergoing pneumonectomy or oesophagogastrectomy. 13 22 Although this test is technically less demanding than formal cardiopulmonary exercise testing, it does require standardization of procedures to produce reproducible and meaningful results. Obviously, immobile and patients with pain will not be able to perform this test.
Cardiopulmonary exercise testing
The gold standard for objective and comprehensive assessment of overall functional capacity is the individual measurement of oxygen uptake and carbon dioxide elimination by using a symptom-limited, submaximal, incremental cardiopulmonary exercise test (CPET). The advantage of this test is that it assesses both the cardiac and the respiratory components of exercise. It provides additional useful information on ECG changes, and on cardiac and ventilatory function. The main measures of interest are peak oxygen consumption (VO 2 peak) and AT. AT is defined as the point at which anaerobic metabolism starts to increase because oxygen delivery to the muscles no longer meets exercise-induced oxygen demand. The thresholds for classifying patients as increased risk are usually set at VO 2 If performed and interpreted appropriately, CPET provides a wealth of additional information beyond standard cardiac stress tests which can potentially assist in the perioperative management of complex cardiovascular and pulmonary disease. 24 25 However, CPET requires complex equipment and highly trained personnel for correctly performing the test and interpreting the results; it is not feasible in the immobile patient, the individual positive predictive values of VO 2 peak and AT remain to be determined, and identification of the AT is not always straightforward. The results of the DASI questionnaire, the ISWT, and the cycle CPET do not necessarily agree. Although a significant correlation between measured oxygen consumption and both ISWT and DASI has been reported, and although both ISWT and DASI were satisfactory predictors of VO 2 peak . 17 Overall, however, the CPET provided more robust information than did Duke's score and shuttle testing. It remains to be seen whether such relatively objective information modifies perioperative management in a way which improves perioperative outcome.
Cardiac risk factors
The cardiac risk factors listed in the ESC guidelines 1 ( Table 5) are those of the Lee revised cardiac risk index (RCRI) 26 except for high-risk surgery which is not included because it is separately considered in the context of surgical risk ( Table 3) . The risk factors are meant to predict cardiac outcome independently. The ESC guidelines recommend using clinical risk indices for postoperative risk stratification (I, B) and specifically to use the Lee RCRI for perioperative risk stratification (I, A). Such clear recommendation is somewhat surprising because cardiac risk indices have several limitations. First, there are general problems with using cardiac risk factors for individual risk stratification. Clinical risk factors do not specify the duration of exposure to the risk factor and thus do not reliably reflect the severity of disease. Definition and diagnosis of risk factors such as angina pectoris, prior myocardial infarction, and heart failure vary and can be highly subjective. Therefore, adding as much objective information as possible [e.g. functional capacity, results of CPET, echocardiographic LV assessment, and concentrations of BNP, NT-proBNP, and C-reactive protein (CRP) in the case of suspected heart failure] is important.
Secondly, there are statistical problems with risk indices. They have very low positive predictive value. Even in the highrisk class IV of the RCRI (≥3 risk factors), only 11% of the population suffered a perioperative cardiovascular event. Discrimination between classes is poor. The 95% confidence intervals of the complication rates show large overlaps in the prediction of risk between the risk classes.
The likelihood ratio is another measure of the ability of a risk index to discriminate between degrees of risk. 27 The accepted low and high values of likelihood ratios for 
Non-invasive testing
Non-invasive tests are performed to obtain information on possible LV dysfunction, myocardial ischaemia, and valvular dysfunction. Resting ECG, echocardiography, and myocardial imaging techniques and cardiac stress tests (exercise ECG, stress echocardiography, stress myocardial perfusion imaging) have very low (0 -33%) positive predictive values for perioperative cardiac events 18 (i.e. likely absence of perioperative cardiac events, despite abnormal test result). Stress tests will primarily detect flow-limiting lesions, but not non-flow-limiting plaques. However, the latter often consist of vulnerable plaques and are frequently the source of perioperative myocardial infarction. 28 29 Not surprisingly then, non-invasive cardiac stress testing may not necessarily be helpful in identifying patients who might benefit from preoperative coronary angiography and coronary revascularization. The indications for performing these tests are, therefore, very restrictive (Tables 6 and 7) .
Coronary angiography
In general, coronary angiography in cardiovascular high-risk patients carries the potential for life-threatening complications. In addition, there is no convincing evidence that preoperative coronary revascularization reliably improves perioperative outcome. Consequently, the indications for preoperative coronary angiography are restrictive and, in general, identical to those in the non-operative setting (Table 8) . Before performing a preoperative coronary angiography, it should be clear beforehand that the patient is a potential candidate for subsequent preoperative coronary revascularization, which necessitates a prior detailed discussion of the implications of preoperative coronary revascularization (e.g. possible postponement of surgery and need for anti-platelet therapy) between medical care givers and the patient. Preoperative coronary angiography merely to confirm the existence of coronary artery disease is rarely indicated. If the coronary anatomy found on coronary 
Biomarkers
Coronary artery and myocardial disease are frequently accompanied by increased plasma concentrations of CRP, and of BNP and NT-proBNP reflecting the considerable inflammatory component associated with cardiovascular disease and increased myocardial wall stress, respectively.
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The results of several recent systematic reviews, meta-analyses, 31 32 and observational studies 33 -37 have
shown that elevated preoperative serum concentrations of high-sensitivity CRP, and BNP or NT-proBNP are powerful, independent predictors of adverse postoperative short-and intermediate-term cardiac outcome in major non-cardiac surgery. In addition, preoperative measurements of these biomarkers provide additive prognostic information for major adverse cardiac events and mortality after high-risk surgery. In patients undergoing elective major non-cardiac surgery, both NT-proBNP (cut-off¼301 ng litre 21 ) and CRP (cut-off¼3.4 mg litre 21 ) predicted major perioperative cardiac events better than the Lee RCRI (cut-off¼2). Moreover, the predictive power of the RCRI was improved threefold by including preoperative concentrations of NT-proBNP and CRP. 37 Elevated CRP concentrations did not predict cardiac events better than elevated NT-proBNP concentrations.
The cut-off concentrations of CRP and of BNP and NT-proBNP associated with adverse outcome varied tremendously between studies, indicating that we are far from knowing what a 'normal' preoperative concentration of these biomarkers might be. Measurements of these biomarkers may be helpful in improving individual risk assessment by increasing the uniformly low positive predictive values of clinical scoring systems and of preoperative cardiac stress tests, by possibly being able to estimate the severity of an underlying cardiac condition (particularly in patients with low or unknown functional capacity), and in deciding on the need for additional cardiac assessment. It is undecided whether postponement of surgery for treatment of the underlying cardiovascular disease until normalization or at least improvement of the concentrations of these biomarkers will improve perioperative outcome. It thus remains to be determined how to effectively use preoperative plasma concentrations of CRP, BNP, and NT-proBNP to improve preoperative risk stratification, before we will be able to decide whether preoperative determination of biomarkers will turn out to be the magic bullet of preoperative cardiac risk stratification. 38 According to the ESC guidelines 1 preoperative measurement of plasma concentrations of BNP and NT-proBNP should be considered to obtain independent prognostic information for perioperative and late cardiac events in high-risk patients (IIa, B). Routine measurements of cardiac biomarkers (BNP, NT-proBNP, and cardiac troponins) are not recommended (III, C).
Preoperative coronary revascularization
Despite numerous publications and respective guidelines and recommendations, the issue of preoperative coronary artery revascularization remains highly controversial, mostly because findings of randomized and non-randomized trials have been contradictory. In the Coronary Artery Revascularization Prophylaxis (CARP) study, preoperative coronary artery revascularization before elective vascular surgery was not associated with a survival benefit. 39 Even in cardiac high-risk patients (≥3 cardiac risk factors and extensive stress-induced myocardial ischaemia) undergoing major vascular surgery, preoperative coronary revascularization was neither associated with improved short-term 40 nor longterm outcome. 41 In contrast, in a randomized, prospective trial involving patients with an RCRI ≥2 undergoing peripheral vascular surgery, a strategy of routine preoperative coronary angiography was associated with better short-and long-term cardiac outcome than a strategy in which coronary angiography was only performed if indicated by findings on noninvasive tests. 42 As the only clinically relevant difference between the groups was a higher preoperative myocardial revascularization rate in the routine compared with the selective strategy group (58% vs 40%; P¼0.01), the findings could suggest that selected patients may possibly benefit from a preoperative coronary revascularization. 43 Similarly, in a randomized study of patients undergoing carotid endarterectomy without any clinical and electrocardiographic signs and symptoms of coronary artery disease and normal LV ejection fraction at rest, routine compared with no preoperative coronary angiography was associated with a significantly reduced incidence of postoperative cardiac events. 44 Preoperative coronary angiography was the only independent predictor of postoperative cardiac However, the limiting factor of this study is that coronary angiography was used as the primary and only means of detecting coronary artery disease. It is thus possible that outcome in the patients not undergoing preoperative angiography was worse because they were not adequately assessed for clinically relevant coronary artery disease. It is likely that several of the control patients had poor or unknown functional capacity and ≥3 cardiac risk factors. If these had been managed according to the ESC algorithm (see below), they would have undergone additional preoperative non-invasive cardiac testing. The results of such testing might have affected subsequent management in a way which might have improved outcome in the control group.
Numerous variables must be expected to affect the impact of preoperative coronary artery revascularization on perioperative cardiac outcome. They include morbidity and mortality associated with coronary angiography and revascularization, especially in cardiac high-risk patients, 45 47 indication for coronary artery revascularization (prophylactic to 'get the patient through surgery' vs class IA indication; for symptoms vs for prognosis; class I vs class II recommendation), 48 type of coronary artery revascularization (interventional vs surgical), 49 50 completeness of coronary artery revascularization, 50 and, possibly most importantly, perioperative management of anti-ischaemic, plaque-stabilizing, and anti-platelet medication. 51 In general, because of lack of clear evidence for an outcome benefit of preoperative coronary artery revascularization, and the risk associated with coronary artery revascularization in general (an estimated 5-30% of patients undergoing PCI have evidence of a peri-procedural myocardial infarction), 45 the indications for preoperative coronary artery revascularization should be handled very restrictively 52 and are, in general, the same as those in the non-surgical setting (Table 9 ). However, in this high-risk patient population, the ultimate decision has to be based on individual assessment of medical and surgical short-and long-term prognosis, and on informed patient consent based on such assessment. If preoperative coronary revascularization is to be performed, it must be remembered that the surgical procedure needs to be postponed for at least 2 weeks after balloon angioplasty, 3 months after placement of a bare-metal stent, and 12 months after placement of a drug-eluting stent. If surgical revascularization is to be performed, non-cardiac surgery generally needs to be delayed for about 30 days after revascularization coronary artery bypass graft.
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Cardiac risk assessment algorithm for non-cardiac surgery
The ESC guidelines 1 recommend a systematic, step-wise approach to preoperative cardiac risk assessment for individual risk assessment (Fig. 1) . The extent of preoperative cardiac evaluation will depend on the urgency of the procedure, and on patient and surgical characteristics.
Step 1: assessment of urgency of surgical procedure
In the case of emergency/urgent surgery, no additional preoperative cardiac evaluation or treatment is possible.
Step 2: assessment of presence of active cardiac conditions
In the case of elective surgery, potentially life-threatening active/unstable cardiac conditions (see above) need to be ruled out. Subsequent management (delay, modification or cancellation of planned procedure) will depend on test results and response to treatment.
Step 3: assessment of surgical risk
If a low-risk surgical procedure (Table 3) is planned, surgery can usually be performed without additional cardiac testing. Otherwise, further risk stratification is required.
Step 4: assessment of functional capacity
In the case of intermediate-or low-risk surgery (Table 3) , functional capacity (Table 4) should be assessed. If the patient is able to generate .4 METs in daily life (as indicated by confirmatory answers to the respective questions), perioperative prognosis is usually good (independent of a history of cardiac disease) and surgery can be performed as planned without additional cardiac testing. In patients with documented coronary artery disease or cardiac risk factors, preoperative initiation of statin therapy and a titrated low-dose b-blocker regimen can be considered.
Step 5: re-assessment of surgical risk
As patients with reduced functional reserve carry an increased perioperative cardiac risk, re-assessment of the cardiac risk of the surgical procedure is recommended in patients with unknown or a functional capacity of ≤4 METs. Such patients may undergo intermediate-risk surgery without additional cardiac testing. In this case, optimal cardiovascular medication should be assured and a baseline ECG obtained in patients with cardiac risk factors. If high-risk surgery is planned, cardiac risk factors need to be assessed.
Step 6: assessment of cardiac risk factors
Whereas the first four steps of the management algorithm meet the objective of the ESC guidelines for 'individualized cardiac risk assessment', 1 this is not the case with the following steps because they are based on the RCRI, a populationderived risk index with poor discriminative power. Despite this limitation, it is used in the decision-making for subsequent non-invasive cardiac testing. If such testing would reliably discriminate between low and high risk, the poor discriminative power of the RCRI would not be of a major concern. However, as mentioned above, the positive predictive values of cardiac stress tests are also uniformly very low. The ESC algorithm states that in patients with up to two clinical cardiac risk factors (Table 5) , surgery can be performed as planned after optimization of cardiovascular medication.
Step 7: consideration of non-invasive testing Step
8: interpretation of stress test results
If cardiac stress testing shows no or only mild stress-inducible myocardial ischaemia, the ESC guidelines Consideration of non-invasive testing. Non-invasive testing can also be considered before any surgical procedure for patient counselling, change of perioperative management in relation to type of surgery, and anaesthetic technique
Step 1
Step 2
Step 3
Step 4
Step 5
Step 6
Step 7
Patient or surgery-specific factors dictate the strategy, and do not allow further cardiac testing or treatment. The consultant provides recommendations on perioperative medical management, surveillance for cardiac events, and continuation of chronic cardiovascular medication Treatment options should be discussed in a multidisciplinary team, involving all perioperative physicians because interventions might have implications on anaesthetic and surgical care. For instance, in the presence of unstable angina, if the planned surgical procedure can be delayed, patients can proceed for coronary artery intervention with the initiation of dual antiplatelet therapy; if delay is impossible, surgery is performed as planned under optimal medical therapy
The consultant can identify risk factors and provide recommendations for postoperative care with regard to life style and medical therapy according to European Society of Cardiology (ESC) guidelines to improve long-term outcome
• Preoperative statin therapy and a titrated low-dose β-blocker regimen appear appropriate • Preoperative therapy with angiotensin inhibitors is recommended in patients with systolic left ventricular dysfunction • A preoperative baseline electrocardiogram is recommended in patients with ≥ 1 cardiac risk factor(s) to monitor changes during the perioperative period
In patients with coronary artery disease or cardiac risk factor(s), statin therapy and a titrated low-dose β-blocker regimen can be initiated before surgery Table 3 for risk of surgical procedure.
#
See Table 4 for assessment of functional capacity. See Table 5 for cardiac risk factors.
do not make additional invasive testing mandatory, but recommend to start therapy with statins and titrated low-dose b-blockers (Fig. 2) . Patients with extensive stress-inducible myocardial ischaemia present a challenge. On the one hand, even optimal medical treatment will not necessarily provide sufficient cardioprotection. On the other hand, preoperative prophylactic coronary revascularization usually does not improve perioperative outcome in this patient population. Under these circumstances, a highly individualized approach is required. The very high cardiac risk of the planned surgical procedure needs to be balanced against the possible harms of not performing surgery (e.g. risk of rupture of an abdominal aneurysm). If there is an indication for coronary revascularization, the angiographic findings, patient preference, and the anticipated time interval between coronary revascularization and surgery will influence the method of coronary revascularization (Fig. 2) .
Pharmacological management
When considering the pathophysiology of coronary artery disease, 28 54 55 the proven cardioprotective efficacy of optimal medical therapy in patients with clinically relevant coronary artery disease and the questionable additional benefit of additional coronary revascularization in secondary cardiac prevention, 51 56 -59 the morbidity and mortality associated with coronary artery revascularization, 45 the lack of proven benefit of a prophylactic preoperative coronary revascularization, 39 -41 52 and the increased perioperative risk of patients with coronary artery stents, 53 60 great emphasis must be placed on optimal perioperative medical therapy in high-risk patients. Pharmacological stabilization of coronary plaques (by statins, aspirin, b-blockers, and ACE inhibitors) is probably more effective in reducing perioperative cardiac morbidity and mortality than increasing myocardial oxygen delivery by coronary revascularization. Preoperative optimization of cardiovascular medication is certainly one of the most important, if not the most important aspect of preoperative cardiac management. The importance of strict heart rate control as an independent predictor of outcome remains open to debate. A thorough search for causes of tachycardia other than myocardial ischaemia must be conducted before an elevated heart rate is symptomatically treated with b-blockers. Persistent perioperative tachycardia may well be due to hypovolaemia, pain, anxiety, anaemia, hypothermia, infection, latent heart failure, or pulmonary embolism. In such situations, heart rate control by b-blockers could endanger lives. Especially, anaemic patients may not be tolerating aggressive, heart rate-controlled perioperative b-blocker therapy.
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Statins
In addition to their lipid-lowering effect, statins have the so-called pleiotropic effects which by various mechanisms improve endothelial morphology and function and stabilize coronary plaques. 68 -71 A few non-randomized studies, 72 73 reviews, 74 and meta-analyses 75 76 and a randomized controlled trial including 497 vascular surgery patients 77 have documented perioperative cardioprotection by statins. There is also evidence that preoperative discontinuation of chronic statin therapy is associated with adverse perioperative outcome. 78 79 Overall evidence suggests a benefit of perioperative statin therapy in patients at increased perioperative cardiac risk. 80 -82 Statin therapy may be of benefit even if started only the day before a myocardial ischaemic insult. A single, high loading dose of statin only 1 day before PCI reduced the incidence of periprocedural myocardial injury in elective PCI. 83 84 On the basis of the present evidence, it is recommended to start statin therapy in high-risk patients, optimally between 30 days and at least 1 week before surgery (I, B), and to not discontinue chronic statin therapy before operation (I, C). 1 If statin therapy is discontinued for whatever reason, it should be restarted as soon as possible.
Angiotensin II inhibitors
ACE inhibitors and angiotensin II receptor blockers (ARBs) exert beneficial effects on cardiovascular and other organ (e.g. kidney) function, 85 which may result in amelioration of myocardial ischaemia and LV dysfunction. Perioperative management of ACE inhibitors or ARBs has traditionally been controversial because the risk of worsening myocardial conditions associated with preoperative discontinuation of these drugs must be weighted against the risk of severe hypotension associated with their continuation. Decisionmaking is helped by considering the indication for therapy.
Patients may be receiving ACE inhibitors or ARBs to primarily treat hypertension or LV systolic dysfunction (e.g. after myocardial infarction). Taking into account the high risk associated with decompensation of LV function, in cardiovascular stable patients taking ACE inhibitors or ARBs for treatment of LV dysfunction, the medication should be continued when undergoing high-risk surgery (I, C), and continuation should be considered when undergoing low-or intermediate-risk surgery (IIa, C). 1 In patients taking the medication for treatment of hypertension, transient discontinuation should be considered (IIb, C). All of these recommendations are based on low level evidence, reflecting lack of scientifically solid data.
Antiplatelet therapy
Aspirin Discontinuation of aspirin may be responsible for 15% of all recurrent acute coronary syndromes in patients with documented stabile coronary artery disease. 86 87 Thus, aspirin taken for secondary cardiac prevention should, in general, not be discontinued. 88 Perioperatively, aspirin should only be discontinued if the expected risk of bleeding and its possible sequelae are similar or even higher (e.g. intracranial, posterior eye chamber, prostate surgery) than the known cardiovascular risks of acute discontinuation of aspirin (e.g. non-fatal and fatal myocardial infarction, stroke).
1 53 60 89 90 Dual antiplatelet therapy
After PCI, premature discontinuation of dual antiplatelet therapy (aspirin and an ADP receptor antagonist) is generally associated with increased incidence of acute coronary syndromes and mortality. 91 -94 The recommendations of international cardiology societies regarding the management of patients after acute coronary syndromes or PCI in the nonoperative setting 95 -99 form the basis for respective perioperative recommendations. 1 18 53 98 100 101 Elective surgery should be postponed for at least 6 weeks (preferably 3 months) after placement of a bare-metal stent, and at least 12 months after implantation of a drug-eluting stent to guarantee a sufficient duration of ADP receptor antagonist therapy (e.g. clopidogrel, prasugel, and ticagrelor) for adequate endothelialization. Premature discontinuation increases perioperative cardiac morbidity and mortality without significantly reducing risk of bleeding. 102 103 If surgery needs to be performed within 3 months after placement of a bare-metal stent, and within the first year after implantation of a drug-eluting stent, then similar to the perioperative management of aspirin therapy, dual antiplatelet therapy with aspirin and an ADP receptor antagonist should only be discontinued before operation if the expected risk of bleeding and its possible sequelae are considerably higher (e.g. intracranial, intraspinal, and posterior eye chamber surgery) than the considerable cardiovascular risks associated with acute discontinuation of dual antiplatelet therapy (e.g. non-fatal and fatal myocardial infarction, stroke), and only if surgery cannot be postponed. 1 18 90 If surgery cannot be postponed, at least aspirin should be continued whenever possible.
Conclusion
Although preoperative cardiac management has improved during the past decades, we are not yet in the situation where we can accurately predict individual perioperative risk. 104 There are several reasons for that. First, the individual stress response (e.g. cardiovascular and endocrine) to a given stressor (e.g. a given surgical procedure, haematocrit value) and the individual interactions between pharmacological intervention (e.g. antiplatelet and cardiovascular medication) and intra-and postoperative risk factors (e.g. anaemia, hypercoagulability, hypovolaemia, inflammatory response, and cardiovascular depression) are highly variable. Secondly, and probably more important, preoperative cardiac management is only one aspect of overall perioperative care. There are numerous intra-and postoperative factors (e.g. haemodynamic, endocrine, metabolic, and inflammatory responses; surgical care issues; duration of surgery; hypovolaemia; hypothermia; anaemia; thromboembolism; pulmonary dysfunction; pain) which have been shown to affect overall outcome. 3 105 Not all of them can reliably be predicted or modified in a way to positively affect overall outcome. However, recognition of such factors and aggressive attempts at appropriate intervention may reduce overall risk more than preoperative management in isolation. Such approach may render the before operation high-risk patient a low(er)-risk patient. Conversely, ignoring such approach may render the before operation low-risk patient a high-risk patient. Even optimal preoperative management will only have a positive impact, if antibiotics, intravascular volume, blood components, and nutrition are managed appropriately; minimally invasive surgery with reduced use of surgical tubes and drains is attempted; and adequate postoperative pain relief and care are provided. 105 106 Without defining and subsequently targeting intra-and postoperative risk factors, the benefit of preoperative cardiac management will be limited.
